Research analysts at Deutsche Bank began coverage on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $28.00 price target on the stock. Deutsche Bank’s price target points to a potential upside of 46.98% from the company’s current price.
A number of other research analysts have also commented on KURA. HC Wainwright set a $31.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Wednesday, May 8th. Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Monday, June 17th. BidaskClub lowered Xperi from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 19th. Wedbush assumed coverage on Pinterest in a report on Monday, June 17th. They set an “outperform” rating and a $33.00 price target on the stock. Finally, Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Kura Oncology has an average rating of “Buy” and a consensus price target of $28.00.
KURA stock opened at $19.05 on Thursday. The company has a current ratio of 13.80, a quick ratio of 13.80 and a debt-to-equity ratio of 0.05. Kura Oncology has a 1 year low of $10.20 and a 1 year high of $22.00. The company has a fifty day moving average of $18.89.
In other news, insider Antonio Gualberto sold 18,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.30% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. CWM LLC acquired a new position in Kura Oncology during the first quarter worth about $25,000. Legacy Advisors LLC acquired a new position in Kura Oncology during the first quarter worth about $65,000. Great West Life Assurance Co. Can acquired a new position in Kura Oncology during the fourth quarter worth about $62,000. Legal & General Group Plc grew its holdings in Kura Oncology by 21.7% during the fourth quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after acquiring an additional 923 shares during the period. Finally, BNP Paribas Arbitrage SA grew its holdings in Kura Oncology by 293,950.0% during the first quarter. BNP Paribas Arbitrage SA now owns 5,881 shares of the company’s stock worth $98,000 after acquiring an additional 5,879 shares during the period. 83.89% of the stock is currently owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.